WO2001083464A1 - Derives d'oxadiazole efficaces en matiere de traitement ou de prevention d'etats pathologiques glomerulaire - Google Patents

Derives d'oxadiazole efficaces en matiere de traitement ou de prevention d'etats pathologiques glomerulaire Download PDF

Info

Publication number
WO2001083464A1
WO2001083464A1 PCT/JP2001/003215 JP0103215W WO0183464A1 WO 2001083464 A1 WO2001083464 A1 WO 2001083464A1 JP 0103215 W JP0103215 W JP 0103215W WO 0183464 A1 WO0183464 A1 WO 0183464A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
compound
lower alkyl
glomerular
prodrug
Prior art date
Application number
PCT/JP2001/003215
Other languages
English (en)
Japanese (ja)
Inventor
Toshihiro Shinosaki
Mitsuyoshi Ninomiya
Fumihiko Watanabe
Original Assignee
Shionogi & Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co., Ltd. filed Critical Shionogi & Co., Ltd.
Priority to AU2001248765A priority Critical patent/AU2001248765A1/en
Publication of WO2001083464A1 publication Critical patent/WO2001083464A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Abstract

Cette invention a trait à des compositions pharmaceutiques aux fins du traitement ou de la prévention d'états pathologiques glomérulaires, contenant comme ingrédient actif des composés correspondant à la formule générale (I), ainsi qu'à leurs promédicaments, à leurs sels admissibles du point de vue pharmaceutique ou à leurs solvates. Dans cette formule, R1 représente un hydroxy ou analogue, R2 représente un alkyle de faible poids moléculaire éventuellement substitué ou analogue, R3 représente un hydrogène, R4 représente un arylène éventuellement substitué ou analogue et R5 représente un aryle éventuellement substitué ou analogue.
PCT/JP2001/003215 2000-04-21 2001-04-16 Derives d'oxadiazole efficaces en matiere de traitement ou de prevention d'etats pathologiques glomerulaire WO2001083464A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001248765A AU2001248765A1 (en) 2000-04-21 2001-04-16 Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000120235 2000-04-21
JP2000-120235 2000-04-21

Publications (1)

Publication Number Publication Date
WO2001083464A1 true WO2001083464A1 (fr) 2001-11-08

Family

ID=18631081

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/003215 WO2001083464A1 (fr) 2000-04-21 2001-04-16 Derives d'oxadiazole efficaces en matiere de traitement ou de prevention d'etats pathologiques glomerulaire

Country Status (2)

Country Link
AU (1) AU2001248765A1 (fr)
WO (1) WO2001083464A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613790B2 (en) 2001-04-17 2003-09-02 Pharmacia Corporation Prodrugs of COX-2 inhibitors
WO2003072085A1 (fr) * 2002-02-27 2003-09-04 Shionogi & Co., Ltd. Preparations solides contenant un medicament a peine soluble dans l'eau d'une meilleure absorbabilite
WO2003080041A1 (fr) * 2002-03-27 2003-10-02 Shionogi & Co., Ltd. Remede contre l'arthrite deformante
WO2004092146A2 (fr) * 2003-04-14 2004-10-28 The Institutes For Pharmaceutical Discovery, Llc Acides phenylalcanoiques substitues
JP2006522826A (ja) * 2003-04-11 2006-10-05 ピーティーシー セラピューティクス，インコーポレーテッド １，２，４−オキサジアゾール安息香酸化合物ならびにナンセンス抑制及び疾患の治療のためのその使用
US7358364B2 (en) 2003-04-30 2008-04-15 The Institute For Pharmaceutical Discovery Llc Substituted carboxylic acids
JP2009524611A (ja) * 2006-01-27 2009-07-02 ノバルティス アクチエンゲゼルシャフト 逆イソキサゾール
US7825146B2 (en) 2003-07-30 2010-11-02 Shionogi & Co., Ltd. Sulfonamide derivative having isoxazole ring
JP2011506423A (ja) * 2007-12-10 2011-03-03 アクテリオン ファーマシューティカルズ リミテッド 新規なチオフェン誘導体
US9873677B2 (en) 2014-03-06 2018-01-23 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
US10517853B2 (en) 2015-10-30 2019-12-31 Ptc Therapeutics, Inc. Methods for treating epilepsy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004780A1 (fr) * 1997-07-22 1999-02-04 Shionogi & Co., Ltd. Agent therapeutique ou prophylactique de traitement de la glomerulopathie
WO2000015213A1 (fr) * 1998-09-11 2000-03-23 Shionogi & Co., Ltd. Agent de prevention ou de traitement de l'insuffisance cardiaque congestive

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004780A1 (fr) * 1997-07-22 1999-02-04 Shionogi & Co., Ltd. Agent therapeutique ou prophylactique de traitement de la glomerulopathie
WO2000015213A1 (fr) * 1998-09-11 2000-03-23 Shionogi & Co., Ltd. Agent de prevention ou de traitement de l'insuffisance cardiaque congestive

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613790B2 (en) 2001-04-17 2003-09-02 Pharmacia Corporation Prodrugs of COX-2 inhibitors
JPWO2003072085A1 (ja) * 2002-02-27 2005-06-16 塩野義製薬株式会社 難水溶性薬物の吸収性を改善した固形状製剤
WO2003072085A1 (fr) * 2002-02-27 2003-09-04 Shionogi & Co., Ltd. Preparations solides contenant un medicament a peine soluble dans l'eau d'une meilleure absorbabilite
JP4632288B2 (ja) * 2002-02-27 2011-02-16 塩野義製薬株式会社 難水溶性薬物の吸収性を改善した固形状製剤
WO2003080041A1 (fr) * 2002-03-27 2003-10-02 Shionogi & Co., Ltd. Remede contre l'arthrite deformante
JP4851933B2 (ja) * 2003-04-11 2012-01-11 ピーティーシー セラピューティクス，インコーポレーテッド １，２，４−オキサジアゾール安息香酸化合物ならびにナンセンス抑制及び疾患の治療のためのその使用
US9861617B2 (en) 2003-04-11 2018-01-09 Ptc Therapeutics, Inc. Compositions of 1,2,4-oxadiazole benzoic acid compounds and methods for their use
US10071081B2 (en) 2003-04-11 2018-09-11 Ptc Therapeutics, Inc. Compositions of 1,2,4-oxadiazole benzoic acid compounds and methods for their use
JP2006522826A (ja) * 2003-04-11 2006-10-05 ピーティーシー セラピューティクス，インコーポレーテッド １，２，４−オキサジアゾール安息香酸化合物ならびにナンセンス抑制及び疾患の治療のためのその使用
US9205088B2 (en) 2003-04-11 2015-12-08 Ptc Therapeutics, Inc. Compositions of 1,2,4-oxadiazol benzoic acid compounds and methods for their use
US8975287B2 (en) 2003-04-11 2015-03-10 Ptc Therapeutics, Inc. Methods for using 1,2,4-Oxadiazole benzoic acid compounds
US8796322B2 (en) 2003-04-11 2014-08-05 Ptc Therapeutics, Inc. Methods for using 1,2,4-oxadiazole benzoic acid compounds
US8486982B2 (en) 2003-04-11 2013-07-16 Ptc Therapeutics, Inc. 1,2,4-oxadiazole benzoic acids
US8227494B2 (en) 2003-04-11 2012-07-24 Ptc Therapeutics, Inc. Pharmaceutical compositions of 1,2,4-oxadiazole benzoic acid and their use for the treatment of disease
WO2004092146A2 (fr) * 2003-04-14 2004-10-28 The Institutes For Pharmaceutical Discovery, Llc Acides phenylalcanoiques substitues
WO2004092146A3 (fr) * 2003-04-14 2004-12-29 Inst For Pharm Discovery Inc Acides phenylalcanoiques substitues
US7358364B2 (en) 2003-04-30 2008-04-15 The Institute For Pharmaceutical Discovery Llc Substituted carboxylic acids
US7825146B2 (en) 2003-07-30 2010-11-02 Shionogi & Co., Ltd. Sulfonamide derivative having isoxazole ring
JP2009524611A (ja) * 2006-01-27 2009-07-02 ノバルティス アクチエンゲゼルシャフト 逆イソキサゾール
JP2011506423A (ja) * 2007-12-10 2011-03-03 アクテリオン ファーマシューティカルズ リミテッド 新規なチオフェン誘導体
US9873677B2 (en) 2014-03-06 2018-01-23 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
US10233161B2 (en) 2014-03-06 2019-03-19 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
US10618877B2 (en) 2014-03-06 2020-04-14 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
US10517853B2 (en) 2015-10-30 2019-12-31 Ptc Therapeutics, Inc. Methods for treating epilepsy

Also Published As

Publication number Publication date
AU2001248765A1 (en) 2001-11-12

Similar Documents

Publication Publication Date Title
US6897237B2 (en) MMP-12 inhibitors
TW201121544A (en) Novel phenol derivative
WO2002068407A1 (fr) Compose benzimidazole
WO1999020620A1 (fr) Derive d'isoquinoleine et medicament
TW200400027A (en) Compounds that modulate PPAR activity
WO2000063194A1 (fr) Derives de sulfonamide possedant des noyaux oxadiazole
ES2467097T3 (es) Compuesto de sulfonamida o sal del mismo
KR100542780B1 (ko) 항암 효과를 갖는 옥사디아졸 유도체
WO2001083464A1 (fr) Derives d'oxadiazole efficaces en matiere de traitement ou de prevention d'etats pathologiques glomerulaire
WO2003080042A1 (fr) Inhibiteur de decomposition pour matrice extracellulaire de cartilage
JP4219810B2 (ja) Ｍｍｐ阻害作用を有するスルホンアミド誘導体
KR20030030036A (ko) 티아졸 또는 옥사졸 유도체
EP1491520A1 (fr) Procede de production de bisphenol a
TW201217335A (en) Prostaglandin d synthase inhibitory piperidine compounds
WO2000058278A1 (fr) Derives d'acides amines $g(b)
WO2005012268A1 (fr) Derive sulfonamide comprenant un noyau isoxazole
JP5796872B2 (ja) 第Ｘａ因子阻害剤の結晶性塩
WO2000058280A1 (fr) Derives de sulfonamide carbocyclique
JPWO2006028038A1 (ja) Ｍｍｐ−１３を選択的に阻害するスルホンアミド誘導体
JP2007530424A (ja) 新規Ｎ−ヒドロキシ−４−（３−フェニル−５−メチル−イソオキサゾール−４−ｙｌ）−ベンゼンスルホンアミドの溶媒和物
JPH1017469A (ja) 新規フィブリノーゲン受容体拮抗物質
JPH03133952A (ja) フェニルスルホニルアルキルカルボン酸誘導体
JPH02202857A (ja) アミノアルコキシベンゼン誘導体
TW200304809A (en) Composition for treating osteoarthritis
JPH0812659A (ja) チアゾール誘導体及びこれを含有する医薬製剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 580893

Kind code of ref document: A

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase